Company intelligence / Profile preview

Avectas

Dublin, Ireland

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Avectas has completed successful preclinical studies showing efficient and gentle non-viral gene editing of immune cells for cancer therapy using the Solupore platform; clinical results in humans have not been reported yet

Therapeutic areas: Oncology
Modalities: mRNA-based drugsProteinGene therapyCell therapyCRISPR-based therapyRecombinant protein
Industry: Biotech

Partnerships

Vycellix (US cell and gene therapy developer)CCRM (Canadian cell therapy company)Bluebridge Technologies (Ireland)NIBRT (National Institute for Bioprocessing Research and Training, Ireland)

Beyond the preview

Go deeper on Avectas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avectas.

Explore the full profile